<p>Natera Inc. has announced the launch of its expanded 21-gene Fetal Focus™ single-gene non-invasive prenatal test (sgNIPT), supported by new findings from the blinded prospective EXPAND clinical trial. The results demonstrate the test’s ability to accurately detect a wider range of clinically relevant inherited conditions in fetuses by analyzing cell-free DNA from maternal blood. The updated panel now includes 16 additional genes linked to severe or early-onset diseases, such as Tay-Sachs disease, Gaucher disease, and galactosemia. The research, based on data from over 1,800 participants in the ongoing EXPAND trial, strengthens the case for integrating single-gene NIPT into routine clinical practice, especially when partner testing is not possible. The results have already been analyzed and presented as part of the initial readout of the EXPAND trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260105476429) on January 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Natera Unveils Expanded 21-Gene Fetal Focus Test With High Accuracy in Detecting Inherited Conditions